Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.56 |
| ▸ | CSNK1D | P48730 | 4/20 | 0.54 |
| ▸ | ACP1 | P24666 | 1/20 | 0.53 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.52 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.52 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.52 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.52 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.52 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.52 |
| ▸ | WNT3A | P56704 | 1/20 | 0.49 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.49 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.49 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.49 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16445401 | 1.00 | DYRK1A (0.56) | DYRK1ACSNK1DACP1HDAC3HDAC4 | |
| SCHEMBL16445697 | 0.92 | ACP1 (0.61) | DYRK1ACSNK1DACP1HDAC3HDAC4 | |
| SCHEMBL16444785 | 0.92 | ACP1 (0.61) | DYRK1ACSNK1DACP1HDAC3HDAC4 | |
| SCHEMBL15281306 | 0.92 | ACP1 (0.61) | DYRK1ACSNK1DACP1HDAC3HDAC4 | |
| SCHEMBL16445099 | 0.89 | DYRK1A (0.53) | DYRK1ACSNK1DACP1HDAC3HDAC4 | |
| SCHEMBL16445097 | 0.89 | DYRK1A (0.53) | DYRK1ACSNK1DACP1HDAC3HDAC4 | |
| SCHEMBL16445215 | 0.84 | DYRK1A (0.66) | DYRK1ACSNK1DACP1HDAC3HDAC4 | |
| SCHEMBL16445217 | 0.84 | DYRK1A (0.66) | DYRK1ACSNK1DACP1HDAC3HDAC4 | |
| SCHEMBL18154205 | 0.84 | CSNK1D (0.56) | DYRK1ACSNK1DACP1HDAC3HDAC4 | |
| SCHEMBL18154386 | 0.84 | CSNK1D (0.56) | DYRK1ACSNK1DACP1HDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10357497-B2 | Pro-drugs of riluzole and their method of use for the treatment of amyotrophic lateral sclerosis | Biohaven Pharmaceutical Holding Company Limited (US) | 2019-07-23 | — | — | US | claimed |
| US-9725427-B2 | Prodrugs of riluzole and their method of use | Biohaven Pharmaceutical Holding Company Limited (US) | 2017-08-08 | — | — | US | claimed |
| US-20150148329-A1 | PRO-DRUGS OF RILUZOLE AND THEIR METHOD OF USE FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2015-05-28 | — | — | US | claimed |
| US-20150045401-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2015-02-12 | — | — | US | claimed |
| US-20230202993-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2023-06-29 | — | — | US | disclosed |
| US-20210078962-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2021-03-18 | — | — | US | disclosed |
| US-10844026-B2 | Prodrugs of riluzole and their method of use | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. (US) | 2020-11-24 | — | — | US | disclosed |
| US-20200157069-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2020-05-21 | — | — | US | disclosed |
| US-10562870-B2 | Prodrugs of riluzole and their method of use | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. (US) | 2020-02-18 | — | — | US | disclosed |
| US-20170334870-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2017-11-23 | — | — | US | disclosed |
| US-9725427-B2 | Prodrugs of riluzole and their method of use | Biohaven Pharmaceutical Holding Company Limited (US) | 2017-08-08 | — | — | US | disclosed |
| US-20150045401-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2015-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10357497-B2 | Pro-drugs of riluzole and their method of use for the treatment of amyotrophic lateral sclerosis | CYP1A2, CYP3A5, UGT1A1 | DYRK1A 4244/4885CSNK1D 2698/4885ACP1 3901/4885 |
| US-20170334870-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | APEH, UGT1A9, ALDH3A1 | DYRK1A 3437/4885CSNK1D 1707/4885ACP1 932/4885 |
| US-20230202993-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | APEH, UGT1A9, ALDH3A1 | DYRK1A 3437/4885CSNK1D 1707/4885ACP1 932/4885 |
| US-20210078962-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | APEH, UGT1A9, ALDH3A1 | DYRK1A 3437/4885CSNK1D 1707/4885ACP1 932/4885 |
| US-10844026-B2 | Prodrugs of riluzole and their method of use | APEH, UGT1A9, ALDH3A1 | DYRK1A 3437/4885CSNK1D 1707/4885ACP1 932/4885 |
| US-20150148329-A1 | PRO-DRUGS OF RILUZOLE AND THEIR METHOD OF USE FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | CYP1A2, CYP3A5, UGT1A1 | DYRK1A 4244/4885CSNK1D 2698/4885ACP1 3901/4885 |
| US-10562870-B2 | Prodrugs of riluzole and their method of use | APEH, UGT1A9, ALDH3A1 | DYRK1A 3437/4885CSNK1D 1707/4885ACP1 932/4885 |
| US-20150045401-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | APEH, UGT1A9, ALDH3A1 | DYRK1A 3437/4885CSNK1D 1707/4885ACP1 932/4885 |
| US-20200157069-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | APEH, UGT1A9, ALDH3A1 | DYRK1A 3437/4885CSNK1D 1707/4885ACP1 932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.